The efficacy of trabectedin in treating ovarian cancer

“Ovarian cancers: Evolving paradigms in research and care”

(2016) Ronald D. Alvarez et al.   GYNECOLOGIC ONCOLOGY

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer

(2016) Ronald D. Alvarez et al.   GYNECOLOGIC ONCOLOGY

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

(2016) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial

(2015) D. Lorusso et al.   ANNALS OF ONCOLOGY

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†

(2015) B. J. Monk et al.   ANNALS OF ONCOLOGY

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

(2015) B Colmegna et al.   BRITISH JOURNAL OF CANCER

Unique features of trabectedin mechanism of action

(2015) Annette K. Larsen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies

(2015) Margaret von Mehren et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Comprehensive Safety Evaluation of Trabectedin and Drug–Drug Interactions of Trabectedin-Based Combinations

(2014) Christian Leporini et al.   BIODRUGS

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial

(2013) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors

(2013) Cristiana Sessa et al.   INVESTIGATIONAL NEW DRUGS

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

(2013) José María del Campo et al.   MEDICAL ONCOLOGY

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

(2012) Bradley J. Monk et al.   EUROPEAN JOURNAL OF CANCER

Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives

(2011) J. Sehouli et al.   ANNALS OF ONCOLOGY

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

(2011) R. Thertulien et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies

(2011) Lia Gore et al.   INVESTIGATIONAL NEW DRUGS

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

(2011) Beatriz Pardo et al.   MEDICAL ONCOLOGY

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

(2010) A. Poveda et al.   ANNALS OF ONCOLOGY

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

(2010) S. B. Kaye et al.   ANNALS OF ONCOLOGY

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

(2010) G. Germano et al.   CANCER RESEARCH

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

(2010) Q. Chu et al.   CLINICAL CANCER RESEARCH

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group

(2010) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors

(2010) Laura Vidal et al.   INVESTIGATIONAL NEW DRUGS

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

(2009) J. M. Del Campo et al.   ANNALS OF ONCOLOGY

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

(2009) B. Forouzesh et al.   CLINICAL CANCER RESEARCH

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours

(2009) C. Sessa et al.   EUROPEAN JOURNAL OF CANCER

Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem

(2009) Carmen Cuevas et al.   NATURAL PRODUCT REPORTS

Trabectedin

(2009) M. K. Chuk et al.   ONCOLOGIST

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

(2008) M. von Mehren et al.   ANNALS OF ONCOLOGY

Role of homologous recombination in trabectedin-induced DNA damage

(2008) M. Tavecchio et al.   EUROPEAN JOURNAL OF CANCER